197 related articles for article (PubMed ID: 22095245)
1. Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.
Yano R; Konno A; Watanabe K; Tsukamoto H; Kayano Y; Ohnaka H; Goto N; Nakamura T; Masada M
Int J Clin Oncol; 2013 Feb; 18(1):96-104. PubMed ID: 22095245
[TBL] [Abstract][Full Text] [Related]
2. A Protected Class, An Unprotected Condition, and A Biomarker - A Method/Formula for Increased Diversity in Clinical Trials for the African American Subject with Benign Ethnic Neutropenia (BEN) - CORRIGENDUM.
Ponder R
Am J Law Med; 2023 Dec; 49(4):525. PubMed ID: 37466031
[No Abstract] [Full Text] [Related]
3. Adjuvant treatment for locally advanced gastric cancer: an Asian perspective.
Kim HD; Ryu MH; Kang YK
Gastric Cancer; 2024 May; 27(3):439-450. PubMed ID: 38489111
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes and symptom clusters pattern of chemotherapy-induced toxicity in patients with early breast cancer.
Wiranata JA; Hutajulu SH; Astari YK; Leo B; Bintoro BS; Hardianti MS; Taroeno-Hariadi KW; Kurnianda J; Purwanto I
PLoS One; 2024; 19(2):e0298928. PubMed ID: 38394281
[TBL] [Abstract][Full Text] [Related]
5. Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.
Mita K; Izumi K; Goriki A; Tasaka R; Hatayama T; Shima T; Kato Y; Kamiyama M; Inoue S; Tanaka N; Hoshi S; Okamura T; Yoshio Y; Enokida H; Chikazawa I; Kawai N; Hashimoto K; Fukagai T; Shigehara K; Takahara S; Kadono Y; Mizokami A
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339260
[TBL] [Abstract][Full Text] [Related]
6. Taxanes in the Treatment of Head and Neck Squamous Cell Carcinoma.
Hsieh CY; Lin CC; Chang WC
Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001888
[TBL] [Abstract][Full Text] [Related]
7. How Asian Breast Cancer Patients Experience Unequal Incidence of Chemotherapy Side Effects: A Look at Ethnic Disparities in Febrile Neutropenia Rates.
Lim ZL; Ho PJ; Hartman M; Tan EY; Riza NKBM; Lim EH; Nitar P; Joint Breast Cancer Registry Jbcr ; Wong FY; Li J
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509253
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer.
Miyagi T; Tsuji D; Kawasakai Y; Ishikawa H; Tanaka R; Nakao M; Nakagaki S; Hayashi T; Ayuhara H; Harada T; Tamaki S; Maeda A; Ohashi Y; Arakawa Y; Fujita Y; Yamamoto K; Miyamoto Y; Yano T; Itoh K
Eur J Clin Pharmacol; 2023 Mar; 79(3):407-414. PubMed ID: 36645467
[TBL] [Abstract][Full Text] [Related]
9. Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial.
Izumi K; Shima T; Mita K; Kato Y; Kamiyama M; Inoue S; Tanaka N; Hoshi S; Okamura T; Yoshio Y; Enokida H; Chikazawa I; Kawai N; Hashimoto K; Fukagai T; Shigehara K; Takahara S; Kadono Y; Mizokami A
Eur Urol Open Sci; 2022 Jul; 41():16-23. PubMed ID: 35813251
[TBL] [Abstract][Full Text] [Related]
10. Serum Levels of Stromal Cell-Derived Factor-1α and Vascular Endothelial Growth Factor Predict Clinical Outcomes in Head and Neck Squamous Cell Carcinoma Patients Receiving TPF Induction Chemotherapy.
Chen YH; Chien CY; Wang YM; Li SH
Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453553
[TBL] [Abstract][Full Text] [Related]
11. Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer.
Poon DMC; Chan K; Chan T; Cheung FY; Lam D; Lam M; Law KS; Lee C; Lee EKC; Leung A; Sze H; Tong CC; Wong KCW; Kwong P
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053569
[TBL] [Abstract][Full Text] [Related]
12. Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer.
Nomura H; Tsuji D; Ueno S; Kojima T; Fujii S; Yano T; Daiko H; Demachi K; Itoh K; Kawasaki T
Invest New Drugs; 2022 Apr; 40(2):420-429. PubMed ID: 34792690
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
Ito G; Kawakami K; Aoyama T; Yokokawa T; Nakamura M; Ozaka M; Sasahira N; Hashiguchi M; Kizaki H; Hama T; Hori S
PLoS One; 2021; 16(7):e0254726. PubMed ID: 34260659
[TBL] [Abstract][Full Text] [Related]
14. A Multicenter Study of Docetaxel at a Dose of 100 mg/m
Hirata T; Ozaki S; Tabata M; Iwamoto T; Hinotsu S; Hamada A; Motoki T; Nogami T; Shien T; Taira N; Matsuoka J; Doihara H
Intern Med; 2021 Apr; 60(8):1183-1190. PubMed ID: 33191320
[TBL] [Abstract][Full Text] [Related]
15. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
Hsieh CY; Lein MY; Yang SN; Wang YC; Lin YJ; Lin CY; Hua CH; Tsai MH; Lin CC
BMC Cancer; 2020 Sep; 20(1):832. PubMed ID: 32873270
[TBL] [Abstract][Full Text] [Related]
16. Different treatment efficacies and side effects of cytotoxic chemotherapy.
Li LJ; Chong Q; Wang L; Cher GB; Soo RA
J Thorac Dis; 2020 Jul; 12(7):3785-3795. PubMed ID: 32802458
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study.
Sun N; Shen B; Zhu J; Zhang X; Zhu H; Liang G; Yang D; Lu J; Zhang Y
J Transl Med; 2020 Jun; 18(1):226. PubMed ID: 32513288
[TBL] [Abstract][Full Text] [Related]
18. Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.
Kosaka T; Uemura H; Sumitomo M; Harada K; Sugimoto M; Hayashi N; Yoshimura K; Fukasawa S; Ecstein-Fraisse E; Sunaga Y; Oya M
Jpn J Clin Oncol; 2019 Aug; 49(8):766-771. PubMed ID: 31329922
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine Plus Cisplatin Split
Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series.
Leal JL; Briones J; Herrera ME; Müller B; Nervi B; Mondaca S
Ecancermedicalscience; 2018; 12():875. PubMed ID: 30483355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
